PharmaTher Holdings to resubmit information on ketamine NDA to US FDA by end of February 2025: Toronto Saturday, February 15, 2025, 18:00 Hrs [IST] PharmaTher Holdings Ltd, a spec ...
A recent case report published in the Journal of Psychoactive Drugs tells the story of a middle-aged man who underwent an ...
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the development and commercialization of KETARX™ (Ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, ...
Every generation seems to have an association with an illegal drug. Baby boomers had LSD, Gen X had pills and millennials had ...
Ketamine also has come under increasing scrutiny as a treatment recently, with studies suggesting that for some patients it ...
Ketamine has received a Hollywood makeover. It used to be known as a rave drug (street name special K) and cat anesthetic.
New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D.
Should we give a hallucinogen to patients in compromised mental states?' wonder ketamine's skeptics. The controversy came to a head in 2024 following the death of Matthew Perry. The popular TV ...
The anesthetic ketamine is being hailed as a breakthrough therapy for people with post-traumatic stress disorder (PTSD), treatment-resistant depression and other mood disorders. But the drug does have ...
More than four hours before police arrived, Denise Lozano, a longtime employee of Vista-based natural soap maker Dr.
The FDA did not express concern about the stability of the ketamine submission batches, which achieved 18 months of stability without issue, and no new preclinical and clinical studies were requested.